Followers | 87 |
Posts | 5547 |
Boards Moderated | 2 |
Alias Born | 07/06/2014 |
Friday, April 29, 2022 7:55:11 PM
Recent ALZN News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:30:23 PM
- Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel • Business Wire • 05/22/2024 12:00:00 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:30:15 PM
- Alzamend Neuro Announces Initial Closing of Private Placement • Business Wire • 05/14/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:30:25 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/10/2024 09:06:26 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/10/2024 08:30:31 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/10/2024 10:30:41 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:30:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:20:24 PM
- Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million • Business Wire • 05/09/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/07/2024 08:31:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:30:33 PM
- Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program • Business Wire • 05/07/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:30:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:30:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 09:30:30 PM
- Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients • Business Wire • 12/11/2023 01:00:00 PM
- Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients • Business Wire • 11/20/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 09:30:19 PM
- Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement • Business Wire • 11/16/2023 01:00:00 PM
- Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001 • Business Wire • 11/13/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:30:17 PM
- Alzamend Neuro Announces Reverse Stock Split • Business Wire • 10/30/2023 12:00:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM